Prasco's Generic Mirtazapine Receives Approval in the U.S.
Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, today announced that it has completed the sale of Mirataz® to Dechra Pharmaceuticals PLC (LSE: DPH) for an upfront payment of $43 million, and royalties on worldwide sales.
Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, today announced that it has entered into a transaction for the sale of Mirataz® to Dechra Pharmaceuticals PLC (LSE: DPH) for an upfront payment of $43 million and royalties on worldwide sales.
Aurobindo Pharma USA Inc said it is voluntarily recalling Mirtazapine tablets, used for the treatment of major depressive disorder, in the US market.
Aurobindo Pharma USA, Inc. Issues Voluntary Nationwide Recall of Mirtazapine Tablets
Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, today announced that the U.S. Food and Drug Administration's Center for Veterinary Medicine approved Mirataz (mirtazapine transdermal ointment) for the management of weight loss in cats.
Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, today announced that the European Marketing Authorization application for Mirataz™ (mirtazapine transdermal gel) has been submitted to the European Medicines Agency (EMA). The EMA has accepted the submission for review, with the official acceptance date of December 21, 2017.
Drug firm Zydus Cadila has received the US health regulator's nod to market Mirtazapine orally disintegrating tablets, an anti depressant, in the American market.
Zydus Pharm’s Generic Mirtazapine Receives Approval In US
Enforcement Report - Week of March 22, 2017